EUCTR2007-004823-39-IT进行中（未招募）1 期
A Phase III, Randomized, Open-Label, 3-Arm Study To Determine the Efficacy and Safety of Lenalidomide (Revlimid) Plus Low-Dose Dexamethasone When Given Until Progressive Disease or for 18 Four-Week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-Week Cycles in Patients with Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation (IFM 07-01) - FIRST
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,590
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Must understand and voluntarily sign informed consent form
- •2.Age ≥ 18 years at the time of signing consent
- •3.Previously untreated, symptomatic multiple myeloma as defined by the 3 criteria below:
- •MM diagnostic criteria (all 3 required):
- •Monoclonal plasma cells in the bone marrow ≥10% and/or presence of a biopsy-proven plasmacytoma
- •Monoclonal protein present in the serum and/or urine
- •Myeloma-related organ dysfunction (at least one of the following)
- •[C] Calcium elevation in the blood (serum calcium >10.5 mg/l or upper limit of normal)
- •[R] Renal insufficiency (serum creatinine >2 mg/dL)
- •[A] Anemia (hemoglobin <10 g/dL or 2 g < normal)
- •[B] Lytic bone lesions or osteoporosis
- •AND have measurable disease by protein electrophoresis analyses as defined by the following:
- •IgG multiple myeloma: Serum monoclonal paraprotein (M-protein) level 1.0 g/dL or urine M-protein level 200 mg/24 hours
- •IgA multiple myeloma: Serum M-protein level 0.5 g/dL or urine M-protein level 200 mg/24 hours
- •IgM multiple myeloma (IgM M-protein plus lytic bone disease documented by skeletal survey plain films): Serum M-protein level ≥ 1.0 g/dL or urine M-protein level ≥ 200mg/24hours
- •IgD multiple myeloma: Serum M-protein level 0.05 g/dL or urine M-protein level 200 mg/24 hours
- •Light chain multiple myeloma: Serum M-protein level 1.0 g/dL or urine M-protein level 200 mg/24 hours
- •AND are at least 65 years of age or older or, if younger than 65 years of age, are not candidates for stem cell transplantation because:
- •The patient declines to undergo stem cell transplantation
- •Stem cell transplantation is not available to the patient due to cost or other reasons
- •4.ECOG performance status of 0, 1, or 2 (see Appendix 21.4)
- •5.Able to adhere to the study visit schedule and other protocol requirements
- •6.Females of child-bearing potential (FCBP)2:
- •a. Must agree to undergo two medically supervised pregnancy tests prior to starting study therapy with either Rd or MPT. The first pregnancy test will be performed within 10-14 days prior to the start of Rd or MPT and the second pregnancy test will be performed within 24 hours prior to the start of Rd or MPT. She must also agree to ongoing pregnancy testing during the course of the study and after the end of study therapy (see Appendix 21.6). This applies even if the patient practices complete and continued sexual abstinence.
- •b.Must commit to either continued abstinence from heterosexual intercourse (which must be reviewed on a monthly basis) or agree to use and be able to comply with effective contraception without interruption, 28 days prior to starting study drug, during the study therapy (including during periods of dose interruptions), and for 28 days after discontinuation of study therapy (see Appendix 21.6).
- •7.Male Patients:
- •a.Must agree to use a condom during sexual contact with a FCBP, even if they have had a vasectomy, throughout study drug therapy, during any dose interruption and after cessation of study therapy (see Appendix 21.6).
- •b.Must agree to not donate semen during study drug therapy and for a period after end of study drug therapy (see Appendix 21.6).
- •8.All patients must:
- •a.Have an understanding that the study drug could have a potential teratogenic risk.
- •b.Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy (see Appendix 21.6).
排除标准
- •1.Previous treatment with antimyeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid [i.e., less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 28 days (4 weeks) of randomization]).
- •2.Any serious medical condition that places the patient at an unacceptable risk if he or she participates in this study.
- •3.Pregnant or lactating females.
- •4.Any of the following laboratory abnormalities:
- •Absolute neutrophil count (ANC) < 1,000/L (1.0 x 109/L)
- •Untransfused platelet count < 50,000 cells/L (50 x 109/L)
- •Serum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN)
- •5.Renal failure requiring hemodialysis or peritoneal dialysis.
- •6.Prior history of malignancies, other than multiple myeloma, unless the patient has been free of the disease for 3 years. Exceptions include the following:
- •Basal cell carcinoma of the skin
- •Squamous cell carcinoma of the skin
- •Carcinoma in situ of the cervix
- •Carcinoma in situ of the breast
- •Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
- •7.Patients who are unable or unwilling to undergo antithrombotic therapy.
- •8.Peripheral neuropathy of > grade 2 severity.
- •9.Known HIV positivity or active infectious hepatitis, type A, B, or C.
- •10.Primary AL (immunoglobulin light chain) amyloidosis and myeloma complicated by amyloidosis
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast CancerErbB2 Positive Locally Recurrent or Metastatic Breast CancerMedDRA version: 14.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007803-10-BGWyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company479
进行中（未招募）
1 期
A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast CancerErbB2 Positive Locally Recurrent or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2008-007803-10-FRWyeth Research, Division of Wyeth Pharmaceuticals, Inc.1,200
进行中（未招募）
1 期
A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast CancerEstudio de fase 3, aleatorizado, abierto y de dos grupos, de neratinib más paclitaxel versus trastuzumab más paclitaxel como tratamiento de primera línea en el cáncer de mama localmente recurrente o metastático positivo para ErbB-2ErbB2 Positive Locally Recurrent or Metastatic Breast CancerCáncer de mama localmente recurrente o metastático positivo para erbB-2.MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2008-007803-10-ESWyeth Research, Division of Wyeth Pharmaceuticals, Inc.1,200
进行中（未招募）
1 期
A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast CancerErbB2 Positive Locally Recurrent or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2008-007803-10-GRWyeth Research, Division of Wyeth Pharmaceuticals, Inc.479
进行中（未招募）
不适用
A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer - NDErbB2 Positive Locally Recurrent or Metastatic Breast Cancer.MedDRA version: 12.0Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2008-007803-10-ITWyeth Research, Division on Wyeth Pharmaceuticals, Inc.1,200